Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (IA) or a pharmaceutically acceptable salt thereof:




formula (IA)

wherein:

**Y**$^1$ and **Y**$^2$ are both O;

**z** is $NR^8$, O or S;

**n** is 0 or 1;

**W** is $NR^1$, $CR^1R^2$ or a bond;

**V** is $NR^{15}SO_2$;

**t** is 0 or 1;

**B** is a group selected from aryl, heteroaryl and heterocyclyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, $C_{1-4}$alkyl ~~(~~optionally substituted by $R^9$ or $C_{1-4}$alkoxy or one or more halo~~)~~, $C_{2-4}$alkenyl ~~(~~optionally substituted by halo or $R^9$~~)~~, $C_{2-4}$alkynyl ~~(~~optionally substituted by halo or $R^9$~~)~~, $C_{3-6}$cycloalkyl ~~(~~optionally substituted by $R^9$ or one or more halo~~)~~, $C_5$-

$_{6}$cycloalkenyl (optionally substituted by halo or $R^9$), aryl (optionally substituted by halo or $C_{1-4}$alkyl), heteroaryl (optionally substituted by halo or $C_{1-4}$alkyl), heterocyclyl (optionally substituted by $C_{1-4}$alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is $C_{2-4}$alkenyl or $C_{2-4}$alkynyl, each being optionally substituted by a group selected from $C_{1-4}$alkyl, $C_{3-6}$cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $-CONHR^9$, $-CONR^9R^{10}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $C_{1-4}$alkyl or $C_{1-4}$alkoxy;

**$R^1$** and **$R^2$** are independently hydrogen or a group selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{3-6}$cycloalkyl and $C_{5-6}$cycloalkenyl which the group may be optionally substituted by halo, cyano, nitro, hydroxy or $C_{1-4}$alkoxy;

**$R^3$**, **$R^4$**, **$R^5$** and **$R^6$** are independently hydrogen or a group selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{3-6}$cycloalkyl, $C_{5-6}$cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{2-4}$alkynyl, $C_{3-6}$cycloalkyl (optionally substituted by one or more $R^{17}$), aryl (optionally substituted by one or more $R^{17}$), heteroaryl (optionally substituted by one or more $R^{17}$), heterocyclyl, $-OR^{18}$, $-SR^{19}$, $-SOR^{19}$, $-SO_2R^{19}$, $-COR^{19}$, $-CO_2R^{18}$, $-CONR^{18}R^{20}$, $-NR^{16}COR^{18}$, $-SO_2NR^{18}R^{20}$ and $-NR^{16}SO_2R^{19}$;

or **$R^1$** and **$R^3$** together with the nitrogen or carbon atoms and carbon atom to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatoms groups selected from NH, O, S, SO and $SO_2$ where the ring is optionally substituted on carbon by $C_{1-4}$alkyl, $C_{1-3}$alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or $C_{1-4}$alkyl;

or **$R^3$** and **$R^4$** together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and $SO_2$ where the ring is optionally substituted on carbon by $C_{1-4}$alkyl, $C_{1-3}$alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl and/or $C_{1-4}$alkyl;

or $\mathbf{R^3}$ and $\mathbf{R^5}$ together with the carbon atoms to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and $SO_2$ where the ring is optionally substituted on carbon by $C_{1-4}$alkyl, $C_{1-3}$alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or $C_{1-4}$alkyl;

or $\mathbf{R^5}$ and $\mathbf{R^6}$ together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and $SO_2$ where the ring is optionally substituted on carbon by $C_{1-4}$alkyl, $C_{1-3}$alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or $C_{1-4}$alkyl;

$\mathbf{R^7}$ is hydrogen or a group selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, heteroalkyl, $C_{3-7}$cycloalkyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{3-7}$cycloalkyl, heterocyclyl, aryl, heteroaryl or heteroalkyl; and wherein the group from which $R^7$ may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, $C_{1-4}$alkyl, nitro, halo$C_{1-4}$alkyl, heteroalkyl, aryl, heteroaryl, hydroxy$C_{1-4}$alkyl, $C_{3-7}$cycloalkyl, heterocyclyl, $C_{1-4}$alkoxy$C_{1-4}$alkyl, halo$C_{1-4}$alkoxy$C_{1-4}$alkyl, $-COC_{1-4}$alkyl, $-OR^{21}$, $-NR^{21}R^{22}$, $-CO_2R^{21}$, $-SR^{25}$, $-SOR^{25}$, $-SO_2R^{25}$, $-NR^{21}COR^{22}$, $-NR^{21}CO_2R^{22}$, $-CONR^{21}R^{22}$ and $-NHCONR^{21}R^{22}$;

or $\mathbf{R^3}$ and $\mathbf{R^7}$ together with the carbon atoms to which they are each attached and $(CR^5R^6)_n$ form a saturated 5- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and $SO_2$ where the ring is optionally substituted on carbon by $C_{1-4}$alkyl, $C_{1-3}$alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or $C_{1-4}$alkyl;

$\mathbf{R^8}$ is selected from hydrogen or methyl;

$\mathbf{R^9}$ and $\mathbf{R^{10}}$ are independently hydrogen, $C_{1-6}$alkyl or $C_{3-6}$cycloalkyl;

or $\mathbf{R^9}$ and $\mathbf{R^{10}}$ together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

$\mathbf{R^{11}}$ is $C_{1-6}$alkyl or $C_{3-6}$cycloalkyl;

$\mathbf{R^{12}}$ and $\mathbf{R^{13}}$ are independently selected from hydrogen, $C_{1-6}$alkyl and $C_{3-6}$cycloalkyl;

$\mathbf{R^{15}}$ is hydrogen or $C_{1-3}$alkyl;

$\mathbf{R^{16}}$ is hydrogen or $C_{1-6}$alkyl;

$\mathbf{R^{17}}$ is selected from halo, $C_{1-6}$alkyl, $C_{3-6}$cycloalkyl and $C_{1-6}$alkoxy;

$\mathbf{R^{18}}$ is hydrogen or a group selected from $C_{1-6}$alkyl, $C_{3-6}$cycloalkyl, $C_{5-6}$cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl$C_{1-4}$alkyl and heteroaryl$C_{1-4}$alkyl where the group is optionally substituted by one or more halo;

$\mathbf{R^{19}}$ and $\mathbf{R^{25}}$ are independently a group selected from $C_{1-6}$alkyl, $C_{3-6}$cycloalkyl, $C_{5-6}$cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl$C_{1-4}$alkyl and heteroaryl$C_{1-4}$alkyl where the group is optionally substituted by one or more halo;

$\mathbf{R^{20}}$ is hydrogen, $C_{1-6}$alkyl or $C_{3-6}$cycloalkyl;

or $\mathbf{R^{18}}$ and $\mathbf{R^{20}}$ together with the nitrogen atom to which they are attached form a heterocyclic 4- to 7- membered ring;

$\mathbf{R^{21}}$ and $\mathbf{R^{22}}$ are independently hydrogen, $C_{1-4}$alkyl, halo$C_{1-4}$alkyl, aryl and aryl$C_{1-4}$alkyl;

provided a compound of formula (IA) is not 1-(4-methyl-2,5-dioxoimidazolidin-4-yl)-*N*-[4-(4-chlorophenoxy)phenyl]methanesulphonamide.

2. (Currently amended) A compound of formula (IB) or a pharmaceutically acceptable salt thereof:




formula (IB)

wherein:

$\mathbf{Y^1}$ and $\mathbf{Y^2}$ are independently O;

**z** is $NR^8$, O or S;

**n** is 0 or 1;

**W** is $NR^1$;

**V** is $SO_2$ or CO;

**t** is 0 or 1;

**B** is a group selected from aryl, heteroaryl and heterocyclyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, $C_{1-4}$alkyl (optionally substituted by $R^9$ or $C_{1-4}$alkoxy or one or more halo), $C_{2-4}$alkenyl (optionally substituted by halo or $R^9$), $C_{2-4}$alkynyl (optionally substituted by halo or $R^9$), $C_{3-6}$cycloalkyl (optionally substituted by $R^9$ or one or more halo), $C_{5-6}$cycloalkenyl (optionally substituted by halo or $R^9$), aryl (optionally substituted by halo or $C_{1-4}$alkyl), heteroaryl (optionally substituted by halo or $C_{1-4}$alkyl), heterocyclyl (optionally substituted by $C_{1-4}$alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is $C_{2-4}$alkenyl or $C_{2-4}$alkynyl, each being optionally substituted by a group selected from $C_{1-4}$alkyl, $C_{3-6}$cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $-CONHR^9$, $-CONR^9R^{10}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $C_{1-4}$alkyl or $C_{1-4}$alkoxy;

provided that when t is 0 such that B is directly attached to the oxygen atom shown in formula (IB) and B is monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl and n is 0 then the monocyclic group that is B is substituted on one of the atoms adjacent to the atom to which the oxygen is attached, by a group selected from those listed above in the definition of B which optionally substitute B;

$\mathbf{R^1}$ and $\mathbf{R^3}$ together with the nitrogen and carbon atoms to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing a further heteroatom group selected from NH, O, S, SO and $SO_2$ where the ring is optionally substituted on carbon by $C_{1-4}$alkyl, fluoro or $C_{1-4}$alkoxy and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or $C_{1-4}$alkyl;

$\mathbf{R^4}$, $\mathbf{R^5}$ and $\mathbf{R^6}$ are independently hydrogen or a group selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{3-6}$cycloalkyl, $C_{5-6}$cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{2-4}$alkynyl, $C_{3-6}$cycloalkyl

(optionally substituted by one or more $R^{17}$), aryl (optionally substituted by one or more $R^{17}$), heteroaryl (optionally substituted by one or more $R^{17}$), heterocyclyl, $-OR^{18}$, $-SR^{19}$, $-SOR^{19}$, $-SO_2R^{19}$, $-COR^{19}$, $-CO_2R^{18}$, $-CONR^{18}R^{20}$, $-NR^{16}COR^{18}$, $-SO_2NR^{18}R^{20}$ and $-NR^{16}SO_2R^{19}$;

or **$R^5$** and **$R^6$** together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and $SO_2$ where the ring is optionally substituted on carbon by $C_{1-4}$alkyl, fluoro or $C_{1-4}$alkoxy and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or $C_{1-4}$alkyl;

**$R^7$** is hydrogen or a group selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, heteroalkyl, $C_{3-7}$cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{3-7}$cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which $R^7$ may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, $C_{1-4}$alkyl, nitro, halo$C_{1-4}$alkyl, heteroalkyl, aryl, heteroaryl, hydroxy$C_{1-4}$alkyl, $C_{3-7}$cycloalkyl, heterocyclyl, $C_{1-4}$alkoxy$C_{1-4}$alkyl, halo$C_{1-4}$alkoxy$C_{1-4}$alkyl, $-COC_{1-4}$alkyl, $-OR^{21}$, $-NR^{21}R^{22}$, $-CO_2R^{21}$, $-SR^{25}$, $-SOR^{25}$, $-SO_2R^{25}$, $-NR^{21}COR^{22}$, $-NR^{21}CO_2R^{22}$, $-CONR^{21}R^{22}$ and $-NHCONR^{21}R^{22}$;

**$R^8$** is selected from hydrogen or methyl;

**$R^9$** and **$R^{10}$** are independently hydrogen, $C_{1-6}$alkyl or $C_{3-6}$cycloalkyl;

or **$R^9$** and **$R^{10}$** together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

**$R^{11}$** is $C_{1-6}$alkyl or $C_{3-6}$cycloalkyl;

**$R^{12}$** and **$R^{13}$** are independently selected from hydrogen, $C_{1-6}$alkyl and $C_{3-6}$cycloalkyl;

**$R^{16}$** is hydrogen or $C_{1-6}$alkyl;

**$R^{17}$** is selected from halo, $C_{1-6}$alkyl, $C_{3-6}$cycloalkyl and $C_{1-6}$alkoxy;

**$R^{18}$** is hydrogen or a group selected from $C_{1-6}$alkyl, $C_{3-6}$cycloalkyl, $C_{5-6}$cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl$C_{1-4}$alkyl and heteroaryl$C_{1-4}$alkyl where the group is optionally substituted by one or more halo;

**$R^{19}$** and **$R^{25}$** are independently a group selected from $C_{1-6}$alkyl, $C_{3-6}$cycloalkyl,

$C_{5-6}$cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl$C_{1-4}$alkyl and heteroaryl$C_{1-4}$alkyl where the group is optionally substituted by one or more halo;

$\mathbf{R^{20}}$ is hydrogen, $C_{1-6}$alkyl or $C_{3-6}$cycloalkyl;

or $\mathbf{R^{18}}$ and $\mathbf{R^{20}}$ together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

$\mathbf{R^{21}}$ and $\mathbf{R^{22}}$ are independently hydrogen, $C_{1-4}$alkyl, halo$C_{1-4}$alkyl, aryl and aryl$C_{1-4}$alkyl.

3. (Currently amended) A compound according to claim 1 ~~or 2~~ wherein t is 1.

4. (Currently amended) A compound according to claim 1 wherein B is phenyl, naphthyl, pyridyl, imidazolyl, quinolinyl, cinnolyl, isoquinolinyl, thienopyridyl, naphthyridinyl, 2,5-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, thienopyrimidinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, indolizinyl, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and isoindolinyl, where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, $C_{1-4}$alkyl (optionally substituted by one or more fluoro), $C_{2-4}$alkynyl, heteroaryl, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is vinyl or ethynyl optionally substituted by $C_{1-4}$alkyl; and $R^9$ and $R^{10}$ are as defined in claim 1.

5. (Currently amended) A compound according to claim 1 wherein B is bicyclic aryl, bicyclic heteroaryl or bicyclic heterocyclyl optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, $C_{1-4}$alkyl (optionally substituted by $R^9$ or $C_{1-4}$alkoxy, or one or more halo), $C_{2-4}$alkenyl (optionally substituted by halo or $R^9$), $C_{2-4}$alkynyl (optionally substituted by halo or $R^9$), $C_{3-6}$cycloalkyl (optionally substituted by $R^9$ or one or more halo), $C_{5-6}$cycloalkenyl (optionally substituted by

halo or $R^9$), aryl (optionally substituted by halo or $C_{1-4}$alkyl), heteroaryl (optionally substituted by halo or $C_{1-4}$alkyl), heterocyclyl (optionally substituted by $C_{1-4}$alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; and $R^9$, $R^{10}$ and $R^{11}$ are as defined in claim 1.

6. (Currently amended) A compound according to claim 1 ~~or 3~~ wherein B is 2-methylquinolin-4-yl or 2,5-dimethylphenyl.

7. (Currently amended) A compound according to claim 2 wherein t is 1 and B is phenyl, naphthyl, pyridyl, imidazolyl, quinolinyl, cinnolyl, isoquinolinyl, thienopyridyl, naphthyridinyl, 2,5-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, thienopyrimidinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, indolizinyl, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and isoindolinyl, where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, $C_{1-4}$alkyl (optionally substituted by one or more fluoro), $C_{2-4}$alkynyl, heteroaryl, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is vinyl or ethynyl optionally substituted by $C_{1-4}$alkyl; and $R^9$ and $R^{10}$ are as defined in claim 2.

8. (Currently amended) A compound according to claim 2 wherein B is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, $C_{1-4}$alkyl (optionally substituted by $R^9$ or one or more halo), $C_{2-4}$alkenyl (optionally substituted by halo or $R^9$), $C_{2-4}$alkynyl (optionally substituted by halo or $R^9$), $C_{3-6}$cycloalkyl (optionally substituted by $R^9$ or one or more halo), $C_{5-6}$cycloalkenyl (optionally substituted by halo or $R^9$), aryl (optionally substituted by halo or $C_{1-4}$alkyl), heteroaryl (optionally substituted by halo or $C_{1-4}$alkyl), heterocyclyl (optionally substituted by $C_{1-4}$alkyl), –

$SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is $C_{2-4}$alkenyl or $C_{2-4}$alkynyl, each being optionally substituted by a group selected from $C_{1-4}$alkyl, $C_{3-6}$cycloalkyl, aryl, heteroaryl, heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $-CONHR^9$, $-CONR^9R^{10}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $C_{1-4}$alkyl or $C_{1-4}$alkox; and $R^9$, $R^{10}$ and $R^{11}$ are as defined in claim 2.

9. (Original) A compound according to claim 2 wherein B is 2-methylquinolin-4-yl.

10. (Currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein $R^7$ is hydrogen or a group selected from $C_{1-4}$alkyl, aryl$C_{1-4}$alkyl, heteroaryl$C_{1-4}$alkyl, heterocyclyl$C_{1-4}$alkyl, aryl, heteroaryl, heterocyclyl and $C_{3-5}$cycloalkyl which group is optionally substituted by cyano, $C_{1-4}$alkyl, halo, $-OR^{21}$, $-CO_2R^{21}$ and $-NR^{21}CO_2R^{22}$.

11. (Currently amended) A compound according to ~~any one of claims 1 to 9~~ claim 1 wherein $R^7$ is hydrogen or a group selected from $C_{1-4}$alkyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl optionally substituted by one or more $C_{1-4}$alkoxy, fluoro, $-COC_{1-3}$alkyl or $-SO_2C_{1-3}$alkyl.

12. (Currently amended) A compound according to ~~any one of claims 1 to 9~~ claim 1 wherein $R^7$ is $C_{1-4}$alkyl optionally substituted by halo, hydroxy, $C_{1-4}$alkoxy or amino.

13-14. (Cancelled)

15. (Currently amended) A method of treating inflammatory diseases, autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy ~~in a warm-blooded animal, such as man, in need of such~~

~~treatment~~ which comprises administering ~~to said animal an effective amount of~~ a compound according to ~~any one of claims 1 to 12~~ claim 1.

16. (Currently amended) A pharmaceutical composition comprising a compound according to claim 1 ~~or claim 2~~ and a pharmaceutically-acceptable diluent or carrier.

17. (Currently amended) A process for preparing a compound according to claim 1 ~~or claim 2~~, ~~comprises~~ comprising the steps of converting a ketone or aldehyde of formula (IIA) or (IIB) into a compound of formula (IA) or (IB);




formula (IIA) or (IIB) formula (IA) or (IB)

and thereafter if necessary:

i) converting a compound of the formula (IA) or (IB) into another compound of the formula (IA) or (IB);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

18. (Original) A process for preparing a compound according to claim 1 which when W is $NR^1$ comprises:



formula (VIIIA) formula (IA)

reaction of an amine of formula (VIIIA) with a suitable chlorosulphonamide intermediate under standard sulphonamide formation conditions; or

when W is a bond or $CR^1R^2$, comprises



formula (XVA) formula (IA)

reaction of a hydantoin sulphonyl chloride of formula (XVA) with a suitable chlorosulphonamide intermediate under standard sulphonamide formation conditions;

and thereafter if necessary:

i) converting a compound of the formula (IA) into another compound of the formula (IA);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.